Cited by 123Bone Metabolism and DiseasesBone health and treatmentsBone health and osteoporosis research

Bisphosphonate-osteoclasts: Changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients

Jobke, Björn, Milovanovic, Petar, Amling, Michael, Busse, Björn·2014·Bone

Abstract

Osteoclasts are unique cells capable of bone resorption and therefore have become a major target in osteoporosis treatment strategies. Bisphosphonates suppress bone turnover via interference with the internal enzymatic cell system of osteoclasts leading to cytoskeletal disruption. This mechanism found its clinical relevance in reducing bone resorption, stabilizing bone mass and reducing fracture risk in osteoporosis patients. However, knowledge about specific in vivo changes in osteoclast cell morphology and function is still insufficient. We examined osteoclasts in 23 paired bone biopsies from osteoporosis patients (18 males, 5 females; age: 52.6±11.5yrs) under nitrogen-containing bisphosphonate administration with a mean treatment duration of three years. Formalin-fixed, undecalcified sections were assessed by qualitative and quantitative bone histomorphometry, where the osteoclast morphology, nuclei, distribution, location as well as resorption parameters were investigated to obtain information about cell function and viability. After three years of treatment, resorption parameters decreased significantly while the number of osteoclasts remained unchanged. Out of 23 patients, nine developed previously termed "giant-osteoclasts" with increased size, numerous nuclei (>10 nuclei/Oc) and oftentimes detachment from the bone surface. These cells frequently had pycnotic nuclei and other morphological signs suggestive of osteoclast apoptosis. Characteristic large-sized osteoclasts were uniquely found in patients treated with nitrogen-containing bisphosphonates, thus being clearly distinguishable from giant-osteoclasts in other bone disorders such as Paget disease, secondary hyperparathyroidism or osteopetrosis. The resorption indices of large-sized osteoclasts, specifically the eroded perimeter and erosion depth, revealed significantly reduced values but not an entirely inhibited resorption capability. Bisphosphonate-osteoclasts' viability and affinity to bone seem significantly disturbed while the apoptotic process may be prolonged for a yet unknown period of time in favor of maintaining a low bone turnover.

Integrity signals

Registry

Crossref · 10.1016/j.bone.2013.10.024

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These osteoclasts showed decreased resorption competency and prolonged apoptosis characteristics.

    “These osteoclasts indeed showed decreased resorption competency and prolonged apoptosis characteristics.”
  • The presence of distinct giant hypernucleated osteoclasts per se in patients undergoing long-term NBP treatment did not necessarily indicate an increase in osteoclast aggressiveness.

    “The presence of distinct giant hypernucleated osteoclasts per sé in patients undergoing long-term treatment with nitrogen bisphosphonates (NBPs), as discovered by Weinstein et al.155 and confirmed by others,156 did not necessarily indicate an increase in osteoclast aggressiveness.”

The citation lists haven’t been fetched yet

References 76 · Cited by 123

Authors
Jobke, B., Milovanovic, P., Amling, M., & Busse, B.
Affiliations
  • University Medical Center Hamburg-Eppendorf (DE)
  • University of Belgrade (RS)
Corresponding author
Busse, Björn
Venue
Bone
Publisher
Elsevier BV
Published
2014-02
Volume
59
Pages
37-43
ISSN
  • 1873-2763 (ISSN-L)
  • 8756-3282
OpenAlex
W1979440035
Cited by
123
References
76
Citations by year
2026: 5 · 2025: 2 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 11 · 2020: 14 · 2019: 14 · 2018: 10 · 2017: 7 · 2016: 11 · 2015: 18 · 2014: 6
FWCI
5.22
Type
journal article
Language
en
Open access
closed
Locations
  • Bone (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (BU 2562/2-1)
  • Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (III45005)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
osteoclasts, nitrogen-containing bisphosphonates, osteoporosis, osteoclast morphology, osteoclast apoptosis, bone resorption, bone turnover, antiresorptive therapy, bone histomorphometry
MeSH terms
Bone Resorption, Diphosphonates, Female, Humans, Male, Middle Aged, Nitrogen, Osteoclasts, Osteoporosis, Apoptosis, Cell Size, Cell Shape, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review